Efficacy of Stepped Care Treatment for Chronic Discogenic Low Back Pain Patients with Modic I and II Changes

Overview

Journal Interv Pain Med

Date 2024 Sep 6

PMID 39239218

Authors

Heidi Mylenbusch

Michiel Schepers

Elmar Kleinjan

Marije Pol

Henk Tempelman

Hanneke Klopper-Kes

Affiliations

Soon will be listed here.

Abstract

Objective: This study investigated whether patients with Modic changes (MC) of types I, I/II, and II would respond to an anti-inflammatory-based, stepped care treatment with three treatment steps: first, oral administration of NSAIDs, 2 × 200 mg celecoxib daily for two weeks; second, an intradiscal steroid injection (ID) with dexamethasone and cefazolin; and third, oral treatment with antibiotics (AB), 3 × 1 g amoxicillin daily for 100 days.

Design: This was an observational clinical study based on analyses of categorical data of patient-reported outcome measurements.

Subjects: Subjects were consecutive patients with chronic low back pain (CLBP), diagnosed by assessment of anamnestic signs of inflammation; a pain score ≥6 on the Numeric Pain Rating Scale (NPRS); a mechanical assessment; MC I, I/II, or II based on MRI; and lack of response to conservative treatment.

Methods: From January 1, 2015, to December 31, 2021, 833 eligible patients were selected for the stepped care treatment. A total of 332 patients completed requested follow-up questionnaires at baseline and 12 months (optional at 3 and 6 months). Primary outcomes were pain (at least 50 % pain relief) and/or a minimum of 40 % improvement in functionality as measured by the Roland Morris Disability Questionnaire (RMDQ) or the Oswestry Disability Questionnaire (ODI). Secondary outcome measures were use of pain medication and return to work.

Results: At 1 year of follow-up, 179 (53.6 %) of 332 patients reported improvement according to the responder criteria. Of the 138 patients that had received only NSAIDs, 88 (63.8 %) had improved. In addition, 50 (56.8 %) of the 183 patients that had received ID had improved, and 41 (38.7 %) of the 106 patients treated with AB had improved. None of the patients reported complications. 12.0 % of patients using AB stopped preterm due to undesirable side effects.

Conclusion: Treatment with a stepped care model for inflammatory pain produced clinically relevant, positive reported outcomes on pain and/or function. Our stepped care model appears to be a useful, safe, and cost-saving treatment option that is easily reproducible. Further studies, including randomized controlled trials and analyses of subgroups, may help to develop a more patient-tailored approach and further avoidance of less-effective treatments and costs.

References

Wise J . Study proposes antibiotics as possible new treatment for some types of chronic low back pain. BMJ. 2013; 346:f2988. DOI: 10.1136/bmj.f2988. View

Zhang Y, Zhao C, Jiang L, Chen X, Dai L . Modic changes: a systematic review of the literature. Eur Spine J. 2008; 17(10):1289-99. PMC: 2556462. DOI: 10.1007/s00586-008-0758-y. View

Chen Y, Yang H, Zhang L, Wang Y, Zou J . Analyzing the Influence of Modic Changes on Patients with Lower Back Pain Undergoing Conservative Treatment. Pain Res Manag. 2019; 2019:8185316. PMC: 6444235. DOI: 10.1155/2019/8185316. View

Boisson M, Lefevre-Colau M, Rannou F, Nguyen C . Active discopathy: a clinical reality. RMD Open. 2018; 4(1):e000660. PMC: 5905838. DOI: 10.1136/rmdopen-2018-000660. View

Dudli S, Fields A, Samartzis D, Karppinen J, Lotz J . Pathobiology of Modic changes. Eur Spine J. 2016; 25(11):3723-3734. PMC: 5477843. DOI: 10.1007/s00586-016-4459-7. View

Ohtori S, Inoue G, Ito T, Koshi T, Ozawa T, Doya H . Tumor necrosis factor-immunoreactive cells and PGP 9.5-immunoreactive nerve fibers in vertebral endplates of patients with discogenic low back Pain and Modic Type 1 or Type 2 changes on MRI. Spine (Phila Pa 1976). 2006; 31(9):1026-31. DOI: 10.1097/01.brs.0000215027.87102.7c. View

Fayad F, Lefevre-Colau M, Rannou F, Quintero N, Nys A, Mace Y . Relation of inflammatory modic changes to intradiscal steroid injection outcome in chronic low back pain. Eur Spine J. 2007; 16(7):925-31. PMC: 2219668. DOI: 10.1007/s00586-006-0301-y. View

Carragee E . Intradiscal treatment of back pain. Spine J. 2011; 11(2):97-9. DOI: 10.1016/j.spinee.2011.01.015. View

Modic M, Masaryk T, Ross J, Carter J . Imaging of degenerative disk disease. Radiology. 1988; 168(1):177-86. DOI: 10.1148/radiology.168.1.3289089. View

10.

Burke J, Watson R, McCormack D, Dowling F, Walsh M, Fitzpatrick J . Intervertebral discs which cause low back pain secrete high levels of proinflammatory mediators. J Bone Joint Surg Br. 2002; 84(2):196-201. DOI: 10.1302/0301-620x.84b2.12511. View

11.

Rao P, Phan K, Reddy R, Scherman D, Taylor P, Mobbs R . DISC (Degenerate-disc Infection Study With Contaminant Control): Pilot Study of Australian Cohort of Patients Without the Contaminant Control. Spine (Phila Pa 1976). 2015; 41(11):935-939. DOI: 10.1097/BRS.0000000000001404. View

12.

Albert H, Sorensen J, Christensen B, Manniche C . Antibiotic treatment in patients with chronic low back pain and vertebral bone edema (Modic type 1 changes): a double-blind randomized clinical controlled trial of efficacy. Eur Spine J. 2013; 22(4):697-707. PMC: 3631045. DOI: 10.1007/s00586-013-2675-y. View

13.

Mitra D, Cassar-Pullicino V, McCall I . Longitudinal study of vertebral type-1 end-plate changes on MR of the lumbar spine. Eur Radiol. 2004; 14(9):1574-81. DOI: 10.1007/s00330-004-2314-4. View

14.

Chen Z, Cao P, Zhou Z, Yuan Y, Jiao Y, Zheng Y . Overview: the role of Propionibacterium acnes in nonpyogenic intervertebral discs. Int Orthop. 2016; 40(6):1291-8. DOI: 10.1007/s00264-016-3115-5. View

15.

Goodman B, Sowa G, Buzanowska M, Willey M, Smith M, Mallempati S . Intradiskal steroids: a viable treatment for low back pain?. PM R. 2014; 6(6):547-55. DOI: 10.1016/j.pmrj.2014.05.006. View

16.

Braten L, Rolfsen M, Espeland A, Wigemyr M, Assmus J, Froholdt A . Efficacy of antibiotic treatment in patients with chronic low back pain and Modic changes (the AIM study): double blind, randomised, placebo controlled, multicentre trial. BMJ. 2019; 367:l5654. PMC: 6812614. DOI: 10.1136/bmj.l5654. View

17.

Storheim K, Espeland A, Grovle L, Skouen J, Assmus J, Anke A . Antibiotic treatment In patients with chronic low back pain and Modic changes (the AIM study): study protocol for a randomised controlled trial. Trials. 2017; 18(1):596. PMC: 5732434. DOI: 10.1186/s13063-017-2306-8. View

18.

ONeill C . Modic changes and intradiscal steroids. Spine J. 2011; 11(2):109-10. DOI: 10.1016/j.spinee.2010.08.032. View

19.

Kovacs F, Abraira V, Arana E, Gervas J, Royuela A, Alvarez-Galovich L . Re: Blondel B, Tropiano P, Gaudart J, Huang RC, Marnay T. Clinical results of lumbar total disc arthroplasty in accordance with Modic signs, with a 2-year-minimum follow-up. Spine 2001;36:2309–15. Spine (Phila Pa 1976). 2012; 37(11):1014-5. DOI: 10.1097/BRS.0b013e3182517849. View

20.

White A, Arnold P, Norvell D, Ecker E, Fehlings M . Pharmacologic management of chronic low back pain: synthesis of the evidence. Spine (Phila Pa 1976). 2011; 36(21 Suppl):S131-43. DOI: 10.1097/BRS.0b013e31822f178f. View